The test panel included hotspot mutations in 17 genes as well as the methylation biomarker ONECUT2 to best cover the shared genetic alterations in UTUC and bladder cancer (primers were listed in Additional file 1: Table S3). This evidence concerns the gene ONECUT2 and urinary bladder cancer.